US2010291657A1PendingUtilityA1

Ribonucleases in which an amino acid sequence of a known ribonuclease is preceded by at least one residue at the n-terminus, and methods of making them recombinantly

Assignee: ALFACELL CORPPriority: Jul 17, 2003Filed: Jun 9, 2010Published: Nov 18, 2010
Est. expiryJul 17, 2023(expired)· nominal 20-yr term from priority
C07K 2319/01A61P 35/00C12N 9/22C12N 15/52C12N 15/09
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

New RNases, and methods of making them, are disclosed. Each includes an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue or leader sequence.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . An isolated protein having the amino acid sequence of SEQ ID NO:60. 
     
     
         21 . (canceled) 
     
     
         22 . A gene that when expressed in a host encodes the protein of  claim 20 . 
     
     
         23 . A gene that when expressed in a host encodes the protein of  claim 21 . 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . An isolated protein having the amino acid sequence of SEQ ID NO:17 preceded at its N-terminal end by a leader sequence, the leader sequence having a) the first residue of SEQ ID NO:64, or b) all residues of SEQ ID NO:64, or c) any fragment of SEQ ID NO:64 that comprises the first residue of SEQ ID NO:64, said isolated protein being active against A-253 cells. 
     
     
         43 . An isolated protein having the amino acid sequence of SEQ ID NO:17 preceded at its N-terminal end by a leader sequence, the leader sequence having a) the first residue of SEQ ID NO:66, or b) all residues of SEQ ID NO:66, or c) any fragment of SEQ ID NO:66 that comprises the first residue of SEQ ID NO:66, said isolated protein being active against A-253 cells. 
     
     
         44 . (canceled) 
     
     
         45 . (canceled) 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . (canceled) 
     
     
         49 . (canceled) 
     
     
         50 . (canceled) 
     
     
         51 . (canceled) 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . (canceled) 
     
     
         55 . (canceled) 
     
     
         56 . (canceled) 
     
     
         57 . An isolated protein having the amino acid sequence of SEQ ID NO:17 preceded at its N-terminal end by a leader sequence, the leader sequence having at least the first and at most all of the residues of SEQ ID NO:62 in order.

Join the waitlist — get patent alerts

Track US2010291657A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.